Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate?
A second report in as many weeks makes the case that Indian CRDMOs are positioned to take advantage of a global supply chain shakeup and Chinese firms stand to lose.
This week, J&J pledged $2 billion to establish a 160,000-square-foot facility at contract manufacturer Fujifilm Biotechnologies’ new biomanufacturing site in North Carolina.
Stockpiling active pharmaceutical ingredients for critical drugs is prudent. However, domestic production of prioritized auxiliary chemicals must be part of strategy.
President Donald Trump’s playbook is to threaten outrageously high industry-specific tariffs in the hope of pressuring drugmakers to come running back to this country.
The agreement includes a 15% tariff on branded pharmaceutical products imported from the European Union to the United States, elevating costs across the pharma value chain.
With the looming threat of Trump’s tariffs on pharmaceuticals, major drugmakers continue to invest billions of dollars in domestic manufacturing in the United States.
This week’s announcement about a new multibillion-dollar investment in PCI Pharma Services is good news for contract development and manufacturing organizations.
Drug manufacturers have been left in a climate of anxious anticipation and a heightened state of uncertainty as the pharma industry waits to see if the president is bluffing.
While the process has been a buzzword for years, offering an alternative to traditional batch manufacturing, industry uptake has been slow. However, the tide may be turning.
The Tar Heel State’s decades-long focus on economic development in life sciences and pharma manufacturing is bearing fruit, as it looks to rival the Bay Area and Boston.
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
